AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29149776
Drug: Nebulized only
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized only salbutamol in the same dose and time as the intervention group
Trial: 26068515
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (12 sessions within 48 hours of injury)
Trial: 21813427
Drug: Risperidone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (up to 4 mg once daily)
Trial: 16765589
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 11378343
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy with additional radiotherapy or tamoxifen
Trial: 3101849
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplements (200,000 IU orally immediately and again the next day)
Trial: 3101849
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplements (200,000 IU orally immediately and again the next day) in children aged under 2 years
Trial: 3101849
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment alone (Control) in children aged under 2 years
Trial: 23720411
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose load (75 grams of carbohydrates in 300 mL water)
Trial: 23720411
Drug: Water (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (300 mL)
Trial: 20580111
Drug: IMRT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT treatment with dose of the day assessment
Trial: 16621327
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of somatostatin to block GH secretion during the first 3 hours of sleep (mainly SWS)
Trial: 12691793
Drug: Quetiapine 25‐75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 25‐75 mg/day
Trial: 11205648
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg, 40 mg, and 20 mg in 2-week intervals for 6 weeks)
Trial: 11205648
Drug: Prednisone (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (during steroid treatment)
Trial: 11205648
Drug: Placebo (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (during steroid treatment)
Trial: 9247506
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0 to 2.5) plus aspirin (150 mg daily)
Trial: 9247506
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin (150 mg daily)
Trial: 8233735
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of Curosurf (200 mg/kg body weight)
Trial: 8233735
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of Curosurf
Trial: 3303425
Drug: Betamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (8 mg) administered intramuscularly for 10 days
Trial: 3303425
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg) administered orally for 10 days
Trial: 3303425
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections and tablets
Trial: 30412448
Drug: Abicipar 1
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar 1 mg
Trial: 30412448
Drug: Abicipar 2
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar 2 mg
Trial: 22109762
Drug: Alprazolam plus
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam plus four intratympanic dexamethasone (ITD) injections
Trial: 22109762
Drug: Alprazolam plus
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam plus four ITD injections plus four intravenous injections of lipo-prostaglandin E(1)
Trial: 16415095
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate 100 mg/day
Trial: 1845926
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker (control)
Trial: 1377245
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of gentamicin and metronidazole
Trial: 1377245
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of gentamicin and metronidazole
Trial: 6462404
Drug: Dexamethasone (steroid)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (steroid) administration during and after lumbar discectomy
Trial: 31477280
Drug: 22 unique
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [UNIQUE Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 unique antibodies (survival-associated antibodies, SAAs) used to stratify patients into low-, medium-, or high-risk survival groups.
Trial: 29801482
Drug: Mwanamphepo (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mwanamphepo (herbal medicine)
Trial: 23145756
Drug: Augmentation technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation technique with hamstring tendon autograft
Trial: 20708814
Drug: Sitagliptin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin administration
Trial: 15812753
Drug: Sequential biventricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential biventricular pacing
Trial: 785608
Drug: Aspirin-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-Placebo
Trial: 30509271
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg daily)
Trial: 31390907
Drug: Pitavastatin Monotherapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin Monotherapy
Trial: 11057103
Drug: RANTES concentrations
RxNorm normalized name: Rantec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RANTES concentrations in BALF from s.A (14.4 pg/ml)
Trial: 11057103
Drug: RANTES concentrations
RxNorm normalized name: Rantec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RANTES concentrations in BALF from s.B (10.9 pg/ml)
Trial: 7586312
Drug: Intravenous bretylium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bretylium (4.7 g)
Trial: 7586312
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (high dose: 1.8 g)
Trial: 7586312
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (low dose: 0.2 g)
Trial: 86040
Drug: String capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: String capsule for duodenal specimen collection
Trial: 28878048
Drug: Interventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional therapy (IT)
Trial: 23833361
Drug: Agaricus sylvaticus
RxNorm normalized name: AGARICUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agaricus sylvaticus supplementation (2.1 g/day)
Trial: 21843336
Drug: Dry cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry cupping treatment (5 sessions over 2 weeks)
Trial: 17454712
Drug: Cessation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation treatment delivered within a randomized clinical trial
Trial: 9753485
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 9 mg once daily for 8 weeks
Trial: 9753485
Drug: Prednisone (PRED)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PRED) 40 mg once daily for the first 2 weeks tapered to 5 mg/day
Trial: 10421972
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (10% solution)
Trial: 10421972
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (5% dextrose)
Trial: 402781
Drug: Intranasal disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal disodium cromoglycate (SCG) 40 mg/day
Trial: 31488762
Drug: Duloxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine + ASA (100 mg)
Trial: 26031187
Drug: Ondansetron treatment
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron treatment identified by IT method
Trial: 26031187
Drug: Ondansetron treatment
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron treatment identified by VT method
Trial: 23358972
Drug: Sunitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib plus FOLFIRI (37.5 mg per day, schedule 4/2)
Trial: 9597554
Drug: Alprazolam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1.0 mg)
Trial: 8338086
Drug: Mesalamine 2
RxNorm normalized name: mesalamine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 2 g daily
Trial: 8338086
Drug: Mesalamine 4
RxNorm normalized name: mesalamine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 4 g daily
Trial: 25921849
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion with SFA + LC n-3 PUFA
Trial: 21224369
Drug: PK-guided docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PK-guided docetaxel dosing
Trial: 21224369
Drug: Body surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body surface area-based docetaxel dosing
Trial: 18996055
Drug: Newly detected
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly detected AF during the first 3 months of implant (4% incidence, 45 of 1170 patients with no AF)
Trial: 18996055
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of AF at the time of ICD implant
Trial: 16868887
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment for 16 weeks
Trial: 9359118
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both medications
Trial: 3980805
Drug: Duo formula
RxNorm normalized name: Effaclar Duo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duo formula group treatment (DFGT), facilitated by a fellow sufferer and a physician, in a series of ten 2-hour weekly sessions.
Trial: 3980805
Drug: Duo formula
RxNorm normalized name: Effaclar Duo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duo formula group treatment (DFGT)
Trial: 29653637
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment
Trial: 10490156
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg fentanyl in 20 ml saline
Trial: 10490156
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg morphine in 20 ml saline
Trial: 10490156
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml saline (control)
Trial: 1822216
Drug: Diltiazem preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem preparations
Trial: 6309993
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (10 mg Sb/kg per dose) every 12 hr for 15 days (group B)
Trial: 6309993
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (10 mg Sb/kg per dose) administered once daily for 31 days (group A)
Trial: 6309993
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (10 mg Sb/kg per dose) every 8 hr for 10 days (group C)
Trial: 29260804
Drug: HF +
RxNorm normalized name: Hydrofluoric acid
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HF + S (10% hydrofluoric acid gel for 60 s and silane for 60 s)
Trial: 29260804
Drug: Co (control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co (control, no surface treatment)
Trial: 24934963
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO)
Trial: 24934963
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (ISO)
Trial: 19602518
Drug: Individual dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual dose of rFSH (50-100 IU/day)
Trial: 19602518
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of rFSH (75 IU/day)
Trial: 11289350
Drug: T4N5 liposome
RxNorm normalized name: T4N5 liposome lotion
DrugBank: Dimericine (DB17833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4N5 liposome lotion
Trial: 11289350
Drug: Placebo liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liposome lotion
Trial: 8018006
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin calcium ointment
Trial: 2920497
Drug: Adaptive control
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive control dosing of etoposide (dose adjustment at 28 hours based on 24-hour plasma level)
Trial: 2920497
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of etoposide (125 mg/m2/day)
Trial: 30212951
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral ibuprofen (10, 5, and 5 mg/kg from days 1 to 3 after birth)
Trial: 30212951
Drug: Conventional ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional ibuprofen treatment (same dosage from days 4 to 6 after echocardiographic confirmation of PDA on day 3)
Trial: 20300016
Drug: L-Arg/L-Orn supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arg/L-Orn supplementation
Trial: 17196132
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Trial: 17196132
Drug: Lamivudine (LMV)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LMV) 100 mg + Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Trial: 17196132
Drug: Lamivudine (LMV)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LMV) 100 mg + Placebo once a day for 12 weeks, followed by 36 weeks of ADV
Trial: 15333417
Drug: HES 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130 (10 mL/kg IV for 30 min)
Trial: 15333417
Drug: HES 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 200 (10 mL/kg IV for 30 min)
Trial: 15333417
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (10 mL/kg IV for 30 min)
Trial: 15333417
Drug: All test
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All test infusions (HES 130, HES 200, Lactated Ringer's)
Trial: 9266259
Drug: Exogenous G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous G-CSF substitution protocols
Trial: 8388285
Drug: Cimetidine suspension
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine suspension 200 mg
Trial: 29576347
Drug: Antibiotics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics treatment for intestinal pathogens
Trial: 22537070
Drug: 10 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/d BSP
Trial: 22537070
Drug: 5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/d BSP
Trial: 20458453
Drug: Rapydan patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapydan patch (lidocaine-tetracaine)
Trial: 20458453
Drug: EMLA patch
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA patch (lidocaine-prilocaine)
Trial: 16448551
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (5-FU, cisplatin, carboplatin, mitomycin C) with radiotherapy (RT)
Trial: 16448551
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy with RT
Trial: 16448551
Drug: Carboplatin-based chemotherapy
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin-based chemotherapy with RT
Trial: 16448551
Drug: Mitomycin C-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin C-based chemotherapy with RT
Trial: 14661322
Drug: Luminal 3
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Luminal 3 mg/kg
Trial: 11032592
Drug: Long-term tamoxifen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term tamoxifen treatment (12-13 years)
Trial: 11032592
Drug: Short-term tamoxifen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term tamoxifen treatment (2-3 years)
Trial: 11032592
Drug: Long-term tamoxifen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term tamoxifen treatment (12-13 years) in node-positive patients
Trial: 11032592
Drug: Long-term tamoxifen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-positive patients
Trial: 11032592
Drug: Long-term tamoxifen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-negative patients
Trial: 8772625
Drug: Oral propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propafenone, mean dose of 615 ± 10 mg day-1
Trial: 8772625
Drug: Oral quinidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinidine, mean dose of 1067 ± 462 mg day-1
Trial: 1482282
Drug: Clomipramine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (specific serotonin reuptake inhibitor)
Trial: 15665713
Drug: DTPa-HBV-IPV/Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV/Hib vaccine coadministered with 7vPn vaccine
Trial: 15665713
Drug: DTPa-HBV-IPV/Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV/Hib vaccine alone
Trial: 2242793
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 suppositories 2.5 mg 1‐2 a day
Trial: 321170
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (iron dextran, 100 mg elemental iron)
Trial: 321170
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (ferrous sulphate, 100 mg elemental iron)
Trial: 31741350
Drug: Picosecond laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picosecond laser treatment
Trial: 31741350
Drug: Lightening cream
RxNorm normalized name: HYDROQUINONE 2 g in 100 mL TOPICAL CREAM [Dark Spot Lightening Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lightening cream (control)